At Accutar Biology, our mission is to employ Artificial Intelligence to help revolutionize drug discovery. By using our unique data-driven principle to explain the complex physical and chemical nature of biological system, we have created state-of-the-art proprietary Accutar computational platforms to improve efficiencies along each step of preclinical drug discovery, including hit identification, lead optimization, ADME prediction, chemical synthesis design and biological target prediction from small molecules. We also provide additional AI solutions upon customers’ requests.
Numerate has mastered the conflicting demands of complex signal processing by applying advanced, proprietary AI, evolved to use all available data – literally everything the industry currently knows, against multiple, simultaneous drug design objectives. We model real biology and apply our models at a massive scale, sifting through noise to follow signals that elude other approaches.
Data2Discovery enables companies to transform to a new, innovative model for using data in AI-driven drug discovery. We leverage Artificial Intelligence and Machine Learning technologies along with very large sets of linked heterogeneous data, both public and proprietary, to pioneer entirely new ways of discovering and evaluating promising drug leads.